Sandoz Will Launch Biosimilar Epoetin Alfa In Europe At Up To 30 Percent Discount To Branded Products
This article was originally published in The Pink Sheet Daily
Executive Summary
EU approval further demonstrates need for U.S. follow-on pathway, Sandoz VP-Global Head of Biopharma Development Ajaz Hussain tells “The Pink Sheet” DAILY.
You may also be interested in...
Health Canada To Consider Follow-On Biologics Proposal In May
"Subsequent Entry Biologics" would not automatically receive indications held by the reference product, draft guidance says.
Health Canada To Consider Follow-On Biologics Proposal In May
"Subsequent Entry Biologics" would not automatically receive indications held by the reference product, draft guidance says.
Next Round Of Epoetin Alfa Biosimilars To Reach Europe In 2008
European Commission approves marketing for Epo-zeta products Hospira's Retacrit, Stada Arzneimittel's Silapo on basis of similarity to J&J's Procrit.